Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
  2. Co-first authors (contributed equally to the work and the writing).
  3. Corresponding author: David Mischoulon, MD, PhD, 1 Bowdoin Sq, 6th Floor, Boston, MA 02114 ([email protected]).
  4. Department of Psychiatry, Emory University, Atlanta, Georgia
  5. Co-first authors (contributed equally to the work and the writing).
  6. Department of Psychiatry, Emory University, Atlanta, Georgia
  7. Department of Psychiatry, Emory University, Atlanta, Georgia
  8. Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts
  9. Department of Psychiatry, Emory University, Atlanta, Georgia
  10. Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
  11. Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
  12. Department of Psychiatry, Emory University, Atlanta, Georgia
  13. Department of Psychiatry, Emory University, Atlanta, Georgia
  14. Department of Psychiatry, Emory University, Atlanta, Georgia
  15. Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
  16. Department of Medicine, Emory University, Atlanta, Georgia
  17. Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
  18. Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
  19. Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
  20. Co-senior authors (contributed equally to the leadership and study design).
  21. Department of Psychiatry, Emory University, Atlanta, Georgia
  22. Huntsman Mental Health Institute, Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, Utah
  23. Co-senior authors (contributed equally to the leadership and study design).
  1. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018;7:CD003177. PubMed CrossRef
  2. Arca M, Borghi C, Pontremoli R, et al. Hypertriglyceridemia and omega-3 fatty acids: their often overlooked role in cardiovascular disease prevention. Nutr Metab Cardiovasc Dis. 2018;28(3):197–205. PubMed CrossRef
  3. Amminger GP, Schäfer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146–154. PubMed CrossRef
  4. Chang JP-C, Su K-P, Mondelli V, et al. Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacology. 2018;43(3):534–545. PubMed CrossRef
  5. Saunders EFH, Ramsden CE, Sherazy MS, et al. Omega-3 and omega-6 polyunsaturated fatty acids in bipolar disorder: a review of biomarker and treatment studies. J Clin Psychiatry. 2016;77(10):e1301–e1308. PubMed CrossRef
  6. Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in depression: a meta-analysis. Transl Psychiatry. 2019;9(1):190. PubMed CrossRef
  7. Ellulu MS, Khaza’ai H, Abed Y, et al. Role of fish oil in human health and possible mechanism to reduce the inflammation. Inflammopharmacology. 2015;23(2-3):79–89. PubMed CrossRef
  8. Itariu BK, Zeyda M, Hochbrugger EE, et al. Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial. Am J Clin Nutr. 2012;96(5):1137–1149. PubMed CrossRef
  9. Abbate R, Gori AM, Martini F, et al. n-3 PUFA supplementation, monocyte PCA expression and interleukin-6 production. Prostaglandins Leukot Essent Fatty Acids. 1996;54(6):439–444. PubMed CrossRef
  10. Baumann KH, Hessel F, Larass I, et al. Dietary omega-3, omega-6, and omega-9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes: a randomized volunteer study. Arterioscler Thromb Vasc Biol. 1999;19(1):59–66. PubMed CrossRef
  11. Caughey GE, Mantzioris E, Gibson RA, et al. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr. 1996;63(1):116–122. PubMed CrossRef
  12. Meydani SN, Endres S, Woods MM, et al. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr. 1991;121(4):547–555. PubMed CrossRef
  13. Trebble T, Arden NK, Stroud MA, et al. Inhibition of tumour necrosis factor-alpha and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation. Br J Nutr. 2003;90(2):405–412. PubMed CrossRef
  14. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22–33, quiz 34–57. PubMed
  15. de Waard F. Body Mass Index. J Chronic Dis. 1978;31(2):129. PubMed CrossRef
  16. Osimo EF, Baxter LJ, Lewis G, et al. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med. 2019;49(12):1958–1970. PubMed CrossRef
  17. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26(3):477–486. PubMed CrossRef
  18. Lichtenstein AH, Matthan NR, Jalbert SM, et al. Novel soybean oils with different fatty acid profiles alter cardiovascular disease risk factors in moderately hyperlipidemic subjects. Am J Clin Nutr. 2006;84(3):497–504. PubMed CrossRef
  19. Chandler GM, Iosifescu DV, Pollack MH, et al. RESEARCH: validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322–325. PubMed CrossRef
  20. Block G, Wakimoto P, Jensen C, et al. Validation of a food frequency questionnaire for Hispanics. Prev Chronic Dis. 2006;3(3):A77. PubMed
  21. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277. PubMed CrossRef
  22. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. DHEW Pub. No. (ADM) 76-338. National Institute of Mental Health; 1976.
  23. Felger JC, Li Z, Haroon E, et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol Psychiatry. 2016;21(10):1358–1365. PubMed CrossRef
  24. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31–41. PubMed CrossRef
  25. Lenhard W, Lenhard A. Calculation of Effect Sizes. Dettelbach, Germany. Psychometrica website. https://www.psychometrica.de/effect_size.html. Published 2016. Accessed May 9, 2020.
  26. Innes JK, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiometabolic risk factors: a systematic review. Int J Mol Sci. 2018;19(2):532. PubMed CrossRef
  27. Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41(40):3925–3932. PubMed CrossRef
  28. Lamon-Fava S, So J, Mischoulon D, et al. Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation. Prostaglandins Leukot Essent Fatty Acids. 2021;164:102219. PubMed CrossRef
  29. Furuyashiki T, Akiyama S, Kitaoka S. Roles of multiple lipid mediators in stress and depression. Int Immunol. 2019;31(9):579–587. PubMed CrossRef
  30. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? a meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1):34–40. PubMed CrossRef
  31. Rapaport MH, Nierenberg AA, Schettler PJ, et al. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry. 2016;21(1):71–79. PubMed CrossRef
  32. Bruggeman C, O’Day CS. Selective Serotonin Reuptake Inhibitor (SSRI) Toxicity. In: StatPearls. StatPearls Publishing. 2019. Accessed September 1, 2019. NIH website. https://www.ncbi.nlm.nih.gov/books/NBK534815/
  33. Garcia E, Santos C. Monoamine Oxidase Inhibitor Toxicity. In: StatPearls. StatPearls Publishing; NIH website. https://www.ncbi.nlm.nih.gov/books/NBK459386/. 2019. Accessed September 1, 2019.
  34. Khalid MM, Waseem M. Tricyclic Antidepressant Toxicity. In: StatPearls. StatPearls Publishing;. NIH website. https://www.ncbi.nlm.nih.gov/books/NBK430931/. 2019. Accessed September 1, 2019
  35. Chang JP-C, Su K-P, Mondelli V, et al. High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Transl Psychiatry. 2019;9(1):303. PubMed CrossRef
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe now